Cargando…

Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors

For breast cancer patients, BRCA gene mutations are predictive of a good response to chemotherapy, but are hampered by a high risk of bilateral and synchronous or metachronous ovarian cancer. Novel therapies such as PARP-inhibitors have proven effective for BRCA1/2 mutated ovarian cancer. We present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zahari, Mihaela Mărioara, Chiorean, Angelica Rita, Duma, Maria Magdalena, Ungureanu, Andrei, Kacso, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	UMF “Gr. T. Popa” Iasi Publishing House 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565681/ https://www.ncbi.nlm.nih.gov/pubmed/34754911 http://dx.doi.org/10.22551/2019.24.0603.10156

Ejemplares similares

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020)

Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients
por: Ji, Gang, et al.
Publicado: (2021)

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCA(MUT) and BRCA(WT) Ovarian Cancer Cells
por: Gralewska, Patrycja, et al.
Publicado: (2022)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification
por: Gasimli, Khayal, et al.
Publicado: (2022)

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
por: Stossel, Chani, et al.
Publicado: (2023)

Genomic Analyses of Germline and Somatic Variation in High-Grade Serous Ovarian Cancer
por: Adamson, A.W., et al.
Publicado: (2023)

Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer
por: Adamson, A. W., et al.
Publicado: (2023)

Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells
por: Perez, Jesenia M., et al.
Publicado: (2021)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
por: Sahin, Irem Durmaz, et al.
Publicado: (2019)

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
por: Marchetti, Claudia, et al.
Publicado: (2021)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
por: Jia, Yaxun, et al.
Publicado: (2022)

The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high‐grade serous ovarian cancer: a national retrospective audit
por: Frugtniet, B, et al.
Publicado: (2021)

Bilateral Serous Psammocarcinoma of Ovary: Rare Variant Low Grade Serous Carcinoma
por: Jena, Saubhagya Kumar, et al.
Publicado: (2015)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers
por: Lee, Young-Jae, et al.
Publicado: (2017)

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
por: Kim, Se Ik, et al.
Publicado: (2019)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography
por: Sobecki, Janelle N., et al.
Publicado: (2020)

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer
por: van der Biessen, Diane A. J., et al.
Publicado: (2018)

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
por: Cruz, C, et al.
Publicado: (2018)

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
por: Rafii, Saeed, et al.
Publicado: (2017)

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP
por: Yokoyama, Takuhei, et al.
Publicado: (2017)

Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer
por: Lønning, Per E., et al.
Publicado: (2022)

Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction
por: De Jong, Diederick, et al.
Publicado: (2022)

BRCA and Early Events in the Development of Serous Ovarian Cancer
por: George, Sophia H. L., et al.
Publicado: (2014)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
por: Gadducci, Angiolo, et al.
Publicado: (2019)

Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer
por: Shen, Yen Ting, et al.
Publicado: (2019)

Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer
por: Cardenas, Horacio, et al.
Publicado: (2019)

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
por: Launonen, I.-M., et al.
Publicado: (2022)

Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004–2019
por: Winchar, Kelcey, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_df91vqld3mpnmtikmca3rimh72